Asahi Life Asset Management CO. LTD. Decreases Holdings in Cencora, Inc. $COR

Asahi Life Asset Management CO. LTD. trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 11.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,370 shares of the company’s stock after selling 180 shares during the period. Asahi Life Asset Management CO. LTD.’s holdings in Cencora were worth $411,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of COR. Invesco Ltd. raised its holdings in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after buying an additional 1,364,433 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Cencora by 4,459.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after buying an additional 787,858 shares in the last quarter. Nuveen LLC purchased a new position in shares of Cencora during the 1st quarter valued at about $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its holdings in shares of Cencora by 144.4% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after buying an additional 439,008 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of research reports. Mizuho raised their price objective on Cencora from $334.00 to $340.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. UBS Group raised their price target on Cencora from $350.00 to $380.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Finally, Wells Fargo & Company raised their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $329.55.

Cencora Stock Performance

Shares of COR opened at $352.83 on Thursday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a one year low of $223.92 and a one year high of $361.38. The firm has a market capitalization of $68.41 billion, a P/E ratio of 36.30, a PEG ratio of 1.56 and a beta of 0.63. The business has a fifty day moving average of $311.49 and a 200 day moving average of $298.36.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s dividend payout ratio is presently 22.63%.

Insider Activity

In other news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 41,544 shares of company stock valued at $12,230,941 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.